FGF19 and metabolic dysfunction-associated steatotic liver disease: In a newly published paper by Hendriks’ group, demonstrating that genetic susceptibility to NAFLD affects the efficacy of relevant drugs, they found that carrying the PNPLA3 I148M variant attenuates organ response to fatty liver drugs, which is particularly evident in the FXR–FGF19 drug axis, and this study provides evidence for possible future personalized medicine for NAFLD [114].